Relationship between magnetic resonance imaging and molecular pathology in patients with glioblastoma multiforme

Chinese Medical Journal

Volumn 124, Issue 17, 2011, Pages 2589-2592

  Li, Wen Bin ^a,b   Tang, Kai ^a   Zhang, Wei ^a   Yan, Wei ^a   You, Gang ^a   Li, Shao Wu ^a   Zhang, Long ^c   Huang, Yan Jie ^c   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; Magnetic resonance imaging; Molecular pathology

Indexed keywords

KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MOLECULAR PATHOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION;

EDEMA; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052544735     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.17.005     Document Type: Article

References (16)

1. Diehn M, Nardini C, Wang DS, Aldape K, Cha S, Kuo MD. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules, Proc Natl Acad Sci U S A 2008; 105: 5213-5218.
2. Yoshizuka N, Moriuchi R, Mori T, Yamada K, Haseqawa S, Maeda T, et al. An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J Biol Chem 2004; 279: 43998-44004.
3. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007; 282: 5413-5419.
4. Sapi E, Flick MB, Rodov S, Kacinski BM. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res 1998; 58: 1027-1033.
5. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, et al. Relationship between gene expression and enhancement in glioblastoma multiforme. Radiology 2008; 249: 268-277.
6. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006; 66: 159-167.
7. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005; 102: 5814-5819.
8. Mokhtari K, Paris S, Aguirre-Cruz L, Privat N, Criniere E, Marie Y, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 2005; 31: 62-69.
9. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005; 15: 297-310.
10. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci 2007; 8: 610-622.
11. Ambroise MM, Khosia C, Ghosh M, Mallikarjuna VS, Annapurneswari S. The role of immunohistochemistry in predicting behavior of astrocytic tumors. Asian Pac J Cancer Prev 2010; 11: 1079-1084.
12. Martinez R, Rohde V, Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2010; 96: 321-329.
13. Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D, et al. Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys 2002; 52: 996-1001.
14. 6-methylguanine-DNA methyltransferase and Ki-67 with prognosis of glioblastoma patients treated with ACNU. Chin J Neuro-Oncol (Chin) 2006; 4: 200-204.
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
16. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005; 293: 855-862.